Home » Topics » Regulatory

Regulatory
RSS

OraPharma's NDA for MPTS accepted for FDA review

April 27, 2000

Lantus approved by FDA for type I and II diabetes

April 27, 2000

New hope for patients suffering from Sjogren's syndrome: FDA approves cevimeline

April 26, 2000

FDA approves Camptosar as first-line treatment of metastatic colorectal cancer

April 25, 2000

Potential new treatment for traumatic brain injury under study at Boehringer Ingelheim

April 25, 2000

Inhalable MS drug enters phase I trials

April 24, 2000

DepoMed reports phase I results for Metformin GR

April 24, 2000

ATP-sensitive K+ channel blockers reportedly useful for vagal nervous system dysfunction

April 24, 2000

CV Therapeutics develops sustained-release formulations of ranolazine

April 24, 2000

Humalog now available in Europe to treat children with diabetes

April 24, 2000

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...